Jci_page_head_homepage_01 Jci_page_head_homepage_02
Constanza Solis, Gerardo I. Aizencang, Kenneth H. Astrin, David F. Bishop, Robert J. Desnick
Published in Volume 107, Issue 6
J Clin Invest. 2001; 107(6):753–762 doi:10.1172/JCI10642
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

EMSAs of GATA1 and CP2 binding by the URO-synthase erythroid promoter and the α-globin promoter, respectively. EMSAs were performed as described in Methods. (a) Partial sequence of the human and murine (36) URO-synthase erythroid-specific promoters. The location and orientation (<, >) of the GATA1, E-box, and CP2 erythroid binding elements are indicated, as are the four novel promoter mutations. Dots are placed every tenth nucleotide. The heterologous CP2 site from the murine α-globin gene promoter and the GATA1 site from the human SCL gene promoter are shown. (b) The radiolabeled probe is GATA1-1 (see a). K562 nuclear extract was present in lanes 2–8. A 100-fold mass excess of unlabeled competitor is included in the following lanes: lane 3, GATA1-1; lane 4, GATA1-SCL; lane 6, GATA1-1, –70 mutation; lane 7, GATA1-1, –76 mutation. (c) The radiolabeled probe is CP2-α-globin (see a). K562 nuclear extract was present in lanes 2–6. Unlabeled competitor is included in the following lanes: lane 3, CP2-α-globin; lane 4, CP2-1; lane 5, CP2-1(–90); lane 6, CP2-1(–86). (d) The radiolabeled probe was CP2-α-globin (see a). K562 nuclear extract was present in lanes 1 to 3. Lane 2: incubation with preimmune serum and Protein A. Lane 3: incubation with anti-CP2 antibody and Protein A.